Comparative Pharmacology
Head-to-head clinical analysis: TEKAMLO versus TWYNSTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TEKAMLO versus TWYNSTA.
TEKAMLO vs TWYNSTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of aliskiren (direct renin inhibitor) and amlodipine (dihydropyridine calcium channel blocker). Aliskiren inhibits renin, reducing angiotensin I and II formation; amlodipine inhibits calcium ion influx across cardiac and vascular smooth muscle, causing vasodilation.
Twynsta (telmisartan/amlodipine) is a combination of an angiotensin II receptor blocker (ARB) and a dihydropyridine calcium channel blocker (CCB). Telmisartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing AT1 receptors, reducing peripheral resistance. Amlodipine inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, causing vasodilation and reduced blood pressure.
One tablet (40 mg telmisartan/5 mg amlodipine) orally once daily; maximum dose: 80 mg telmisartan/10 mg amlodipine per day.
Twynsta (telmisartan/amlodipine) is available as 40/5 mg, 40/10 mg, 80/5 mg, and 80/10 mg tablets. Recommended starting dose is 40/5 mg once daily. Titrate based on blood pressure response to a maximum of 80/10 mg once daily. Administered orally.
None Documented
None Documented
Amlodipine terminal half-life: 30-50 hours (mean 35 hours), allowing once-daily dosing; steady-state achieved after 7-8 days. Valsartan terminal half-life: ~6 hours, but pharmacodynamic effect persists due to tight AT1 receptor binding.
Telmisartan: terminal half-life ~24 h (allows once-daily dosing). Amlodipine: terminal half-life 30-50 h (provides smooth 24-h coverage).
TEKAMLO (amlodipine/valsartan) excretion: amlodipine is extensively metabolized in the liver with 60% of metabolites excreted renally and 20-25% via feces; unchanged drug in urine <10%. Valsartan is primarily excreted unchanged in feces (70-80%) via biliary elimination, and 13% in urine as unchanged drug.
Telmisartan: predominantly biliary/fecal (≥97% unchanged), renal <1%. Amlodipine: renal (60% as metabolites), fecal (20-25%).
Category C
Category C
Antihypertensive combination
Antihypertensive combination